Everything below concerns thymalfasin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
The history of sertraline dates to the early 1970s when Pfizer chemist Reinhard Sarges invented a novel series of psychoactive compounds, including lometraline, based on the structures of the neuroleptics thiothixene and pinoxepin. Further work on these compounds led to tametraline, a norepinephrine and weaker dopamine reuptake inhibitor. Development of tametraline was soon stopped because of undesired stimulant effects observed in animals. A few years later, in 1977, pharmacologist Kenneth Koe, after comparing the structural features of a variety of reuptake inhibitors, became interested in the tametraline series. He asked another Pfizer chemist, Willard Welch, to synthesize some previously unexplored tametraline derivatives. Welch generated several potent norepinephrine and triple reuptake inhibitors, but to the surprise of the scientists, one representative of the generally inactive cis-analogs was a serotonin reuptake inhibitor. Welch then prepared stereoisomers of this compound, which were tested in vivo by animal behavioral scientist Albert Weissman. The most potent and selective (+)-isomer was taken into further development and eventually named sertraline. Weissman and Koe recalled that the group did not set up to produce an antidepressant of the SSRI type—in that sense their inquiry was not "very goal driven", and the invention of the sertraline molecule was serendipitous. According to Welch, they worked outside the mainstream at Pfizer, and even "did not have a formal project team".
== Medical uses == Olipudase alfa is indicated as an enzyme replacement therapy for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency in people with type A/B or type B. Olipudase alfa is an enzyme replacement therapy, developed to replace patients' deficient or defective enzyme, acid sphingomyelinase, and thereby reduce fat accumulation within cells and relieve some of the symptoms of the disease. Xenpozyme was approved by the European Medicines Agency for the treatment of acid sphingomyelinase deficiency type A/B or type B, and by the US FDA for the treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency.
Antimicrobial resistance means that a microorganism is resistant to an antimicrobial drug that was once able to treat an infection by that microorganism. Resistance is a property of the microbe, not a person or other organism infected by a microbe. All types of microbes can develop drug resistance. Thus, there are antibiotic, antifungal, antiviral and antiparasitic resistance. Antibiotic resistance is a subset of antimicrobial resistance. This more specific resistance is linked to bacteria and thus broken down into two further subsets, microbiological and clinical. Microbiological resistance is the most common and occurs from genes, mutated or inherited, that allow the bacteria to resist the mechanism to kill the microbe associated with certain antibiotics. Clinical resistance is shown through the failure of many therapeutic techniques where the bacteria that are normally susceptible to a treatment become resistant after surviving the outcome of the treatment. In both cases of acquired resistance, the bacteria can pass the genetic catalyst for resistance through horizontal gene transfer: conjugation, transduction, or transformation. This allows the resistance to spread across the same species of pathogen or even similar bacterial pathogens.
The shark population has benefited significantly from the surge in seal numbers following the Marine Mammal Protection Act in 1972, and as many as 800 individual white sharks are documented visiting the Cape Cod area.
== Adaptations and similar concepts == The American philosopher Ken Wilber described a "Great Nest of Being" which he claims to belong to a culture-independent "perennial philosophy" traceable across 3000 years of mystical and esoteric writings. Wilber's system corresponds with other concepts of transpersonal psychology. In his 1977 book A Guide for the Perplexed, the economist E. F. Schumacher described a hierarchy of beings, with humans at the top able mindfully to perceive the "eternal now".
Sources: en.wikipedia.org
In 1998 the BPL began sourcing its plasma from the United States due to concerns over vCJD in the UK. In 2002 the Department of Health (DoH) formed DCI Biologicals Inc to purchase US company Life Resources Inc to supply all of the BPL's plasma. BPL became an operating division within new special health authority, NHS Blood and Transplant, in 2005. This placed BPL alongside the National Blood Service and the organ transplant division, a strategic partnership to safeguard blood, tissues and blood products. On 31 December 2010 the BPL was vested into a limited company, Bio Products Laboratory Ltd, and ownership transferred to the DoH, with BPL Ltd and DCI Biologicals Inc brought under the same DoH holding company, Plasma Resources UK Ltd. On 18 July 2013 it was announced by Business Secretary Vince Cable that Bain Capital had bought 80% of Plasma Resources UK (PRUK) from the DoH for £230m, which included both BPL and DCI Biologicals. The company was subsequently renamed BPL Holdings, with the original BPL site now called BPL Therapeutics and DCI named BPL Plasma. In 2018, when it was the sole owner, the Chinese group Creat had announced that it planned to integrate BPL's operations with German plasma product manufacturer Biotest. In 2022, Creat was required to dispose of its U.S. plasma centers which necessitated a sale of BPL as a whole. The sale was made to Kedrion BioPharma and BPL became a subsidiary of the Kedrion Group.
is the distance traveled by the liquid. More extensive models account for paper tortuosity, pore radius, and paper deformation. Once the medium is fully wetted, subsequent flow is laminar and follows Darcy's law. The average velocity of fluid flow is generalized as,
Moore and another Liverpool biochemist, Edward Whitney, founded the Biochemical Journal in 1906, one year after the creation of the US-based Journal of Biological Chemistry in 1905. Both journals still exist. Moore served as the first Biochemical Journal editor with the journal initially being published by the Liverpool University Press, the 3rd oldest University Press in England. Moore was concerned with the high mortality for the United Kingdom of pulmonary tuberculosis (TB), which he called the ‘Great White Plague', concluding that with 'the foundation of a new National Health Service and the provision of segregation for infectious cases in sanatoria, the disease could be eradicated'. Other holders of the Johnston Chair include RA Morton, FRS HH Rees, the late Trevour Goodwin FRS and the current Head of Department PA Eyers The Liverpool-originated Biochemical Journal was acquired by the London-based Biochemical Club (later renamed the Biochemical Society in 1911.
=== Other pathways === Wnt signaling also regulates a number of other signaling pathways that have not been as extensively elucidated. One such pathway includes the interaction between Wnt and GSK3. During cell growth, Wnt can inhibit GSK3 in order to activate mTOR in the absence of β-catenin. However, Wnt can also serve as a negative regulator of mTOR via activation of the tumor suppressor TSC2, which is upregulated via Dsh and GSK3 interaction. During myogenesis, Wnt uses PA and CREB to activate MyoD and Myf5 genes. Wnt also acts in conjunction with Ryk and Src to allow for regulation of neuron repulsion during axonal guidance. Wnt regulates gastrulation when CK1 serves as an inhibitor of Rap1-ATPase in order to modulate the cytoskeleton during gastrulation. Further regulation of gastrulation is achieved when Wnt uses ROR2 along with the CDC42 and JNK pathway to regulate the expression of PAPC. Dsh can also interact with aPKC, Pa3, Par6 and LGl in order to control cell polarity and microtubule cytoskeleton development. While these pathways overlap with components associated with PCP and Wnt/Calcium signaling, they are considered distinct pathways because they produce different responses.
=== Operation Enduring Freedom VI, 2005–2008 === The 1st Brigade of the 82nd deployed in April 2005 in support of OEF 6, and returned in April 2006. 1st Battalion, 325th Infantry Regiment deployed in support of OEF 6 from July through November 2005. In March 2006, 3rd Battalion (General Support), 82nd Aviation was selected to augment a special operations task force using CH-47 Chinooks and UH-60 Black Hawks. The task force consisted of 75th Ranger Regiment, Special Forces, and 160th Special Operations Aviation Regiment (Airborne). 2007 February 18, seven soldiers from the task force died in a helicopter crash. The deployment would end a month later (March 2007). In January 2007, then Maj. Gen. David M. Rodriguez deployed the division headquarters to Bagram Air Base, Afghanistan, accompanied by 4th BCT and the Aviation Brigade, as Commander, Combined Joint Task Force-82 (CJTF-82) and Regional Command – East for Operation Enduring Freedom VIII. The 3d BCT, 10th Mountain Division (Light Infantry) was extended for 120 days to increase the troop strength against the Taliban spring offensive. Extended to 15-month deployment, 4th BCT, which included 1–508th Infantry Regiment, 2–508th Infantry Regiment, and 4–73rd Cavalry Regiment, 2–321st Field Artillery, and 782nd Brigade Support Battalion, was commanded by then Col. Martin P. Schweitzer and remained in Khowst Province from January 2007 until April 2008. The 2–508th IR worked to establish and maintain firebases in and around the Ghazni province while actively patrolling their operational area.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.